FDA approves injectable form of Bristol Myers Squibb’s cancer drug Opdivo

The U.S. Food and Drug Administration (FDA) has granted approval for an injectable version of Bristol Myers Squibb's (BMY.N) blockbuster cancer drug, Opdivo. This approval marks a significant development in the delivery of the widely used immunotherapy, which has been pivotal in treating various types of cancer. The injectable format offers a new level of convenience and flexibility for patients, simplifying the administration process compared to traditional infusion methods.

Opdivo belongs to a class of drugs known as PD-1 inhibitors, which work by enhancing the immune system's ability to detect and destroy cancer cells. These drugs achieve this by blocking the PD-1 protein, effectively removing the immune system’s natural brakes and allowing it to target cancer more effectively. Alongside Merck's Keytruda (MRK.N), another leading PD-1 inhibitor, Opdivo has revolutionized cancer immunotherapy, offering hope to patients with conditions that were once considered difficult to treat.

Previously, Opdivo was only available as an intravenous infusion, requiring patients to visit a healthcare facility to receive the treatment. The introduction of an injectable version now provides a more accessible option for patients, potentially reducing the time and cost associated with frequent clinic visits. This advancement is expected to improve the overall patient experience while maintaining the drug’s efficacy in combating cancer.